Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq was performed on PANC1 cells after treatment with 0.18 mM sulbutiamine for 48 hours

ABSTRACT: This study aimed to explore the regulatory effect of sulbutiamine on the gene expression profile of human pancreatic cancer PANC1 cells. PANC1 cells cultured in vitro were treated with 0.18 mM sulbutiamine for 48 hours, and untreated PANC1 cells were set as the control group. Total RNA was extracted from cells of each group after treatment, and high-throughput RNA sequencing (RNA-seq) was performed to detect transcriptomic expression changes and screen differentially expressed genes (DEGs). Subsequently, bioinformatics analyses were conducted to analyze the functional enrichment, signaling pathways and protein interaction networks of the identified DEGs, so as to clarify the transcriptomic characteristics of PANC1 cells in response to sulbutiamine intervention. This study reveals the molecular regulatory mechanism of sulbutiamine against pancreatic cancer at the transcriptome level, providing comprehensive transcriptomic experimental evidence for exploring potential therapeutic targets and signaling pathways of sulbutiamine in pancreatic cancer, and laying a theoretical foundation for the research and development of novel adjuvant therapeutic agents for pancreatic cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE334103 | GEO | 2026/09/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq in pancreatic cancer PANC1 cells

Project description:RNA-seq in pancreatic cancer PANC1 cells

| PRJNA542693 | ENA

RNA-seq was performed on PANC1 cells after treatment with 0.18 mM sulbutiamine for 48 hours

Project description:RNA-seq was performed on PANC1 cells after treatment with 0.18 mM sulbutiamine for 48 hours

| PRJNA1473747 | ENA

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

Transcription profiling of human drug-resistant Panc1/mock cells and Panc1 cells expressing wildtype syk

Project description:We recently identified the nonreceptor tyrosine kinase syk as a tumor suppressor in pancreatic ductal adenocarcinoma cells. Reintroduction of syk into Panc1 cells promoted a more differentiated phenotype and retarded invasion and tumorigenic growth. Gene array analysis identified over 2,000 transcripts differentially expressed at FDR<0.01. Among these were members of the MMP2 axis, which were subsequently shown to regulate Panc1 invasion. Experiment Overall Design: Affymetrix global gene arrays were used to analyse differences in gene expression patterns in Panc1 cells stably reexpressing syk, or vector-only mock controls. RNA was harvested from cells grown under identical conditions in standard culture.

2009-09-18 | E-GEOD-18000 | biostudies-arrayexpress

GLI1 knock-down in Panc1 cells

Project description:Panc1 (human pancreatic adenocarcinoma cells) cells were transfected with control siRNA (targeting firefly luciferase, siLuc) or siRNA targeting GLI1 (siGLI1, Pool of four siRNAs). 72h following transfection, RNA was prepared for array analysis.

2012-03-31 | E-MEXP-3379 | biostudies-arrayexpress

Gene expression comparison of drug-resistant Panc1/mock cells and Panc1 cells expressing wildtype syk

Project description:We recently identified the nonreceptor tyrosine kinase syk as a tumor suppressor in pancreatic ductal adenocarcinoma cells. Reintroduction of syk into Panc1 cells promoted a more differentiated phenotype and retarded invasion and tumorigenic growth. Gene array analysis identified over 2,000 transcripts differentially expressed at FDR<0.01. Among these were members of the MMP2 axis, which were subsequently shown to regulate Panc1 invasion. Keywords: Genetic manipulation (stable transgene expression)

2009-09-09 | GSE18000 | GEO

Differential Gene Expression in oxaliplatin-resistant versus unteated PANC1 cells

Project description:We sought to examine changes in gene expression of PANC1 cells with acquired resistance to oxaliplatin chemotherapy. Cultures of PANC1 cells, an established pancreatic cancer cell line, were exposed to oxaliplatin chemotherapy over multiple passages and acquired a stable drug-resistant phenotype labeled as PANC1OR. Previously reported immunofluorescence and western blots indicate that PANC1OR exhibit increased EMT (increased cytoskeletal vimentin, decreased E-cadherin and fibroblast-like morphology). Here we sought to examine more broadly the differential expression of genes associated with acquired drug resistance in these cells.

2024-12-19 | GSE279527 | GEO

Gene expression profiling of PANC1 and BXPC-3 pancreatic cells

Project description:The aim of this study was to characterize the metabolic and gene expression profile of pancreatic cancer cell line like PANC1 and BXPC-3. Furthermore, to assess the effective sensitivity of cancer cell to metabolic targeting in order to predict their response to therapeutic strategies affecting metabolism. Gene expression profile suggested us some pathway involved in metabolic process that could be used, after validation, as in vivo screening for therapeutic sensitivity.

2017-05-09 | E-MTAB-4540 | biostudies-arrayexpress

Gene expression analysis of Panc1 pancreatic cancer cells with shRNA mediated control (GFP) or ZEB1 knockdown

Project description:Epithelial-to-mesenchymal transition (EMT) is a fundamental process in development and disease. If aberrantly activated it is a trigger for tumour progression and metastasis (Thiery et al 2009 Cell). It is now known that EMT activation is also associated with the maintenance of stem-cell properties (Mani et al. 2008 Cell). Since Zinc-finger enhancer binding transcription factor 1 (ZEB1) is a crucial EMT activator, we analyzed the changes in the gene expression profile that accompany shRNA mediated loss of ZEB1 in Panc1 pancreatic cancer cells. Panc1 is a cell line that exhibits relatively high ZEB1 levels and changes to a more benign phenotype upon ZEB1 knock down (Wellner et al. 2009 Nature Cell Biology). Panc1 cells were stably transfected with control (GFP) or ZEB1 shRNA. Upon puromycin selection, single cell clones were picked and characterized. Cells from two control versus two ZEB1 knockdown clones were harvested, total RNA was isolated and processed to hybridization.

2016-06-15 | E-MTAB-3483 | biostudies-arrayexpress

microRNA Expression profiles of parental Panc1 cell lines and Gemcitabine resistance Panc1 cell lines

Project description:Gemcitabine (GEM) is a key drug for treating PDAC, and it is commonly used for adjuvant chemotherapy. Although the majority of PDAC is sensitive to GEM at first, GEM cannot control PDAC for very long, suggesting that PDAC develops resistance to GEM after prolonged exposure. No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses gemcitabine resistant PDAC for its specific miR expression pattern. Gemcitabine resistant variants of Panc1, a human pancreatic adenocarcinoma cell line, were established. MicroRNA screening was investigated by microarray.

2016-04-26 | GSE80616 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data